Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.86 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.86 |
| ▸ | MTOR | P42345 | 19/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443678 | 0.92 | PIK3CA (1.00) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4439345 | 0.92 | PIK3CA (0.84) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4437720 | 0.92 | PIK3CA (0.84) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4441871 | 0.91 | PIK3CA (1.00) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4448984 | 0.90 | PIK3CA (1.00) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4442221 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4437723 | 0.87 | PIK3CA (0.85) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4443287 | 0.84 | PIK3CA (0.83) | PIK3CAPIK3CGMTOR | |
| SCHEMBL4016897 | 0.84 | PIK3CA (0.62) | PIK3CAPIK3CGMTOR | |
| SCHEMBL27803374 | 0.83 | PIK3CA (0.85) | PIK3CAPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125815-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008116129-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| EP-2125815-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116129-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, MTMR1 | PIK3CA 4/4885PIK3CG 16/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.